Shaken baby syndrome in an infant treated for retinopathy of prematurity with anti-VEGF injection.

Abstract

We present the case of an infant who received bevacizumab treatment for retinopathy of prematurity (ROP) and developed retinal hemorrhages 12 weeks later. Although preretinal hemorrhages along the ROP's ridge were a concern for recurrence, we decided to investigate other etiologies because of numerous retinal hemorrhages in different retinal layers and their concentration in the posterior pole. Cranial magnetic resonance imaging revealed a new-onset subdural hemorrhage. Factors that were suspicious for trauma were identified in the detailed history taken from the family by the hospital's child abuse team. This case highlights the importance of considering the characteristics of retinal hemorrhages in infants with ROP and conducting any necessary investigation.

• Authors: Ali Devebacak, Sinan Bekmez, Erdem Eris, Huseyin Mayali, Ilkay Yurtseven, Yagmur Celik, Ozlem Bag
• Journal: Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus (J AAPOS) Vol. 27 Issue 1 Pg. 42-44 (02 2023) ISSN: 1528-3933 [Electronic] United States
• PMID: 36521820 (Publication Type: Case Reports)
• Copyright: Copyright © 2022 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Chemical References

• Bevacizumab
• Angiogenesis Inhibitors

Topics

• Infant, Newborn
• Child
• Infant
• Humans
• Retinal Hemorrhage (therapy)
• Shaken Baby Syndrome (complications, drug therapy)
• Retinopathy of Prematurity (surgery)
• Bevacizumab (therapeutic use)
• Laser Coagulation (adverse effects)
• Intravitreal Injections
• Angiogenesis Inhibitors (therapeutic use)
• Gestational Age